RxDoctor Payments Data

Timothy Wei

Neurology · Walnut Creek, CANPI 1093762825

Payments from drug & device makers

$52,898in general payments, 2019–2025

Across 388 payments — averaging $136.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$22K
  • Teva Pharmaceuticals USA, Inc.$19K
  • Amgen$10K
  • Neurocrine Biosciences, Inc.$269
  • UCB, Inc.$169
  • Bausch Health US, LLC$153
  • plus $736 from 14 others

What the payments were for

  • Speaking & faculty fees$18,70077%
  • Food & beverage$5,36822%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,898 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$509,685
Medicare patients
674
Services billed
21,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate14$81,648
RytaryCarbidopa/Levodopa33$60,706
BotoxOnabotulinumtoxina44$59,390
UbrelvyUbrogepant28$29,501
Nurtec OdtRimegepant Sulfate23$28,668
Ajovy AutoinjectorFremanezumab-Vfrm14$19,949
Aimovig AutoinjectorErenumab-Aooe23$16,701
NeuproRotigotine13$10,778
Zolmitriptan17$3,705
Carbidopa-LevodopaCarbidopa/Levodopa51$2,271
Memantine Hcl ErMemantine Hcl26$1,935
Gabapentin66$1,713
Carbidopa-Levodopa ErCarbidopa/Levodopa27$1,502
Duloxetine Hcl35$1,491
Pregabalin61$966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy$22,228$88,89172 claims
Teva Pharmaceuticals USA, Inc.Copaxone$19,184$81,64814 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$57$61,29047 claims
PfizerNurtec Odt$65$28,66823 claims
UCB, Inc.Neupro$169$10,77813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →